Abstract
Objective To describe the global academic response to COVID-19 during its early stages. The responsiveness of investigators, editorial teams, and publishers was explored.
Design Cross-sectional bibliometric review of COVID-19 literature. A parallel search of Middle East Respiratory Syndrome (MERS) literature was performed for comparison of outcomes.
Data sources MEDLINE and EMBASE databases. The search for COVID-19 studies was performed between 1st November 2019 and 24th March 2020. The search for MERS studies was performed one year earlier between 1st November 2018 and 24th March 2019.
Main outcome measures Investigator-responsiveness was assessed by measuring the volume and type of published research. Editorial-responsiveness was assessed by measuring the time from manuscript submission to acceptance and the availability of original data to support the study results. Publisher-responsiveness was assessed by measuring the time from manuscript acceptance to first publication and the provision of open access.
Results In total, 398 of 2835 COVID-19 and 55 of 1513 MERS search results were eligible. Most COVID-19 studies were clinical reports (n=242; 60.8%) and the majority of these were case series (n=105; 43.4%) and single cases (n=65; 26.9%). The times from manuscript submission to acceptance (median: 5 days (IQR: 3–11) vs 71.5 days (38–106); P<0.001) and acceptance to publication (median: 5 days (IQR: 2–8) vs. 22.5 days (4–48.5-; P<0.001) were strikingly shorter for COVID-19. Almost all COVID-19 (n=396; 99.5%) and MERS (n=55; 100%) studies were available with open-access. Data sharing was infrequent, with original data available for 104 (26.1%) COVID-19 and 10 (18.2%) MERS studies (P=0.203).
Conclusions The early academic response to COVID-19 was characterised by investigators aiming to define the disease. These studies were made rapidly and openly available by editorial and publishing teams. Data sharing practises are an essential target for improvement as the pandemic progresses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: None
Ethical Approval: Not required
Data Sharing: All available data will be available after peer-reviewed publication
Data Availability
All available data will be available after peer-reviewed publication
